After the successful completion of the Oncology conference we are pleased to welcome you to the “Global Summit on Oncology and Cancer Therapy.” The congress is scheduled to take place on November 23-24, 2020 in the beautiful city of New York, USA. This 2020 Oncology Conference will give you exemplary experience and great insights in the field of research. The global Oncology/Cancer drugs market was valued at $97,401 million in 2017, and is estimated to reach at $176,509 million by 2025, registering a CAGR of 7.6% from 2018 to 2025. Cancer is a disease, which involves the abnormal growth of cells that result in the formation of a tumor. However benign tumors are not Cancers. The abnormal tumor cells have the tendency to spread to other local tissues and may also spread to different parts of body through blood and lymphatic system. Different types of Cancers such as lung Cancer, colorectal, breast Cancer and others are predominant among the populace. Treatment of Cancer depends upon the stages of the disease progression. Chemotherapy is majorly used in the earlier stages whereas other therapy options such as targeted therapy drugs, immunological therapy drugs are used in late stage. Cancer has a widespread prevalence worldwide, which has led to rise in demand for Cancer drugs. The key factors that are responsible for the growth of the Oncology/ Cancer drugs market are surge in Cancer research, rise in geriatric population worldwide, and increase in number of collaborations between pharmaceutical companies. In addition, rise in healthcare expenditure worldwide is expected to boost the market expansion. Moreover, high market growth potential in developing nations, rise in number of pipeline products, and upsurge in demand for personalized medicines are expected to create new opportunities for the market players during the forecast period. However, adverse effects associated with the use of Cancer drugs and high costs related with Cancer drug development are the major factors that impede the growth of the market. According to drug class type, the targeted therapy segment occupied the largest Oncology/Cancer drugs market share in 2017. This is due to the ability of targeted therapies to kill only malignant cells, higher efficacy and higher survival rates associated with their use. The immunotherapy segment is expected to show fastest growth during the forecast period, registering a CAGR of 10.4%. This is attributed to surge in incidence of Cancer worldwide and high unmet medical needs in some countries. Immunotherapy drugs are widely accepted as an ideal treatment option as these drugs are potentially harmless to the other living cells of the body which makes them less toxic as compared to other modes of Cancer therapies. Moreover, continuous efforts in R&D to design and develop new immunotherapeutic for the treatment of various Cancer types serves as a key factor for the growth of the Oncology/Cancer drugs market. According to indication, the prostate Cancer segment occupied the largest Oncology/Cancer drugs market share in 2017. This is due to presence of huge geriatric population. The lung Cancer segment is expected to show fastest growth during the forecast period. This is due to technological developments in the field of Cancer diagnostics and rise in the awareness related to the early diagnosis of Cancer. translation. This will be possible due to the fact that the computer will begin to understand and analyse the meaning of the text. Our Mission • To provide the best platform were various ideas can be shared and information can be discussed. • To conduct conferences annually in each and every field of life science in various parts of the world to target maximum audiences. • To conduct outstanding events with our hard work. • To create some value worldwide.
Ahmed Ali Bakr
Background: This paper purpose is to assess the accuracy of two Algorithms, Anisotropic Analytical algorithm (AAA) and Acuros XB (AXB) used for dose calculation in treatment planning system Eclipse TPS (Varian Medical Systems, Palo Alto, CA). Estimating conformity (CI) and homogeneity index (HI) using 6 MV photon energy implemented in true beam linear accelerator Material and methods: CT series of 27 non-small cell lung cancer (NSCLC) patients treated with intensity modulated radiation therapy (IMRT) technique. Complex cases planned for stereotactic radiation body radiosurgery (SBRT) treatment, using (AAA) algorithm. Then recalculate the same plans using Acuros XB algorithm estimating the conformity index (CI) and Homogeneity index (HI) for PTV using dose volume histogram (DVH) for both calculation algorithms were calculated. Results: The results of the part of clinical study showed no significant differences for the mean dose but different noticed in conformity index for the planning target volume (PTV) for both algorithms that was between (1.45±0.55)for AAA and (2.17±0.7) for Acuros XB however the Homogeneity Index difference (0.15±0.07) for AAA and (0.1±0.08) for acuros XB, the maximum dose for PTV are significantly differ about 2.3% to 4.5% between them.
El Hadji Seydou Mbaye
Worldwide, one in eight deaths is due to cancer. Projections based on the GLOBOCAN 2012 estimates predict a substantive increase new cancer cases per year by 2035 in developing countries if preventive measures are not widely applied. According to the World Health Organization (WHO), millions of lives could be saved each year if countries made use of existing knowledge and the best cost-effective methods to prevent and treat cancer. Therefore, the aim of this study is to estimate a provisional budget against cancer in low and middle incomes countries, according the GNI-PPP, the cancer incidence and the number of population.Economically country classification is determining with the Gross national income (GNI), per capita, Purchasing power parity (PPP), according the administrations of the International Monetary Fund (IMF), the World Bank (WB) and the Central Intelligence Agency (CIA). Cancer incidence data presented are based on the most recent data available at IARC. However, population compares estimates from the US Bureau of the Census. The provisional budget is establishing among the guidelines developed by WHO for regional and national cancer control programs according to national economic development. Provisional budget against cancer is estimated to 21,824.998 (thousands of U.S $) for a population of 19,245,344 persons in Niger.
Clinical Microbiology laboratories are continuing to be impacted particularly hard by the COVID 19 global pandemic and the urgent needs to increase testing capacity for both COVID 19 and for other infectious diseases – particularly hospitalized and critical care patients. As an example, blood culture collections have increased. With this increased testing capacity demand, were the coincidental requirements for technology (i.e. instruments), reagents, plastics (i.e. assay trays, pipette tips) and additional technical laboratory staff. A shortage of trained medical laboratory technologists (MLT) remains a challenge and this will likely continue as retirements will outpace new graduates. Technology is promoted as an alternative to staffing shortages with a transition from “traditional” bench microbiology and microscopy to automated and semi-automated platforms including multiplex polymerase chain reaction (PCR), automated Gram staining and total lab automation. Matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) has already revolutionized bacterial/yeast identification in labs with this technology. Such technology advances offer exciting opportunities but have negative consequences related to loss of traditional microbiology skill sets. Clinically, however, clinicians are anxious for accurate results within shorter turn-around-times (TAT) that influence therapeutic decisions and/or patient flow and favor these technological advances. Currently there is a disconnect between availability of equipment (weeks to months for delivery) and availability of the necessary supplies/assays to operate these instruments. Supply chain has been frequently cited as a concern during the COVID 19 pandemic. In some instances, the limiting factor might be availability of a specific pipette tip or reagent. To meet testing demands in our diagnostic laboratory, we are operating similar technology from different vendors in an attempt to secure necessary supplies but this is not a guarantee. This presentation will focus on testing for COVID 19 and other infectious diseases during a time of supply chain issues.
The world is naturally radioactive and approximately 82% of human absorbed radiation doses, which are of control, arise from natural sources such as cosmic, terrestrial and exposure from inhalation or intake radiation sources. In recent years several international studies have been carried out on the effects of low radiation dose. Gamma radiation emitted from natural sources is largely due to primordial radionuclides, mainly 232Th and 238U series and their decay products as well as 40K, which exist at trace levels in the earth’s crust. Their concentration in soils, sands, and rocks depends on the local geology of each region of the world. Naturally occurring radioactive materials generally contain terrestrial-origin radionuclide, left over since the creation of the earth. The present review article was carried out to consider all of natural radiation and some device emitting ionizing radiation such X-rays, CT scans used in Nuclear Medicine, and some equipment in our building today e.g. smoke detector emitting alpha radiation (Americium Beryllium), can promote cancer-capable cells.
Milena Trudes de Oliveira Caires
Peripheral neuropathy is a side effect that often occurs in patients under cancer treatment with Taxanes denominated Chemotherapy-Induced Peripheral Neuropathy (CIPN). It usually affects sensitive nerves, and the symptoms anatomically extend over the extremities (gloves and socks). This condition can cause the reduction or discontinuation of therapy, leading to the increasing use of non-drug strategies which has demonstrated many effective procedures in symptom reduction. Photobiomodulation (PBM) is a non-invasive treatment that has been applied to prevent or manage cancer treatment side effects and is used, among other actions, for peripheral nerve regeneration; however, best parameters must be established. Considering the pathophysiology and the prevalent symptom localization of CIPN, we intend to use the beneficial effects of FBM with red low power laser (LLT) in soles and toes. This study aims to evaluate the efficacy of red LLT applied to soles and toes in symptom relief and quality of life improvement of breast cancer patients with CIPN treated with Taxanes. One patient was selected to receive eight red LLT (660 nm) applications, and its efficacy was measured by using Visual Analysis Scale (VAS) and the DN4 and EORTC QLQ- C30 (version 3.0) questionnaires. This female patient received neoadjuvant treatment with docetaxel due to triple-negative breast cancer and symptoms of CIPN during eight months. After the intervention, the score of DN4 was from 3 to 0, the Symptom Scales EORTC QLQ-C30 was from 45 to 10, the Functional Scales EORTC QLQ-C30 was from 49 to 91, the Global Health Status was from 50 to 83,33, VAS was from 8 to 2, and the subjective improvement was of 80%. This case report showed positive results in the symptom reduction and quality of life improvement of a breast cancer patient treated with red LLT in soles and toes.